The Phenotypic and Genetic Spectrum of Paroxysmal Kinesigenic Dyskinesia in China.

PRRT2 diagnosis genotype-phenotype correlation paroxysmal kinesigenic dyskinesia treatment

Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
08 2020
Historique:
received: 21 08 2019
revised: 23 02 2020
accepted: 28 02 2020
pubmed: 12 5 2020
medline: 28 4 2021
entrez: 12 5 2020
Statut: ppublish

Résumé

Paroxysmal kinesigenic dyskinesia is a spectrum of involuntary dyskinetic disorders with high clinical and genetic heterogeneity. Mutations in proline-rich transmembrane protein 2 have been identified as the major pathogenic factor. We analyzed 600 paroxysmal kinesigenic dyskinesia patients nationwide who were identified by the China Paroxysmal Dyskinesia Collaborative Group to summarize the clinical phenotypes and genetic features of paroxysmal kinesigenic dyskinesia in China and to provide new thoughts on diagnosis and therapy. The China Paroxysmal Dyskinesia Collaborative Group was composed of departments of neurology from 22 hospitals. Clinical manifestations and proline-rich transmembrane protein 2 screening results were recorded using unified paroxysmal kinesigenic dyskinesia registration forms. Genotype-phenotype correlation analyses were conducted in patients with and without proline-rich transmembrane protein 2 mutations. High-knee exercises were applied in partial patients as a new diagnostic test to induce attacks. Kinesigenic triggers, male predilection, dystonic attacks, aura, complicated forms of paroxysmal kinesigenic dyskinesia, clustering in patients with family history, and dramatic responses to antiepileptic treatment were the prominent features in this multicenter study. Clinical analysis showed that proline-rich transmembrane protein 2 mutation carriers were prone to present at a younger age and have longer attack duration, bilateral limb involvement, choreic attacks, a complicated form of paroxysmal kinesigenic dyskinesia, family history, and more forms of dyskinesia. The new high-knee-exercise test efficiently induced attacks and could assist in diagnosis. We propose recommendations regarding diagnostic criteria for paroxysmal kinesigenic dyskinesia based on this large clinical study of paroxysmal kinesigenic dyskinesia. The findings offered some new insights into the diagnosis and treatment of paroxysmal kinesigenic dyskinesia and might help in building standardized paroxysmal kinesigenic dyskinesia clinical evaluations and therapies. © 2020 International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
Paroxysmal kinesigenic dyskinesia is a spectrum of involuntary dyskinetic disorders with high clinical and genetic heterogeneity. Mutations in proline-rich transmembrane protein 2 have been identified as the major pathogenic factor.
OBJECTIVES
We analyzed 600 paroxysmal kinesigenic dyskinesia patients nationwide who were identified by the China Paroxysmal Dyskinesia Collaborative Group to summarize the clinical phenotypes and genetic features of paroxysmal kinesigenic dyskinesia in China and to provide new thoughts on diagnosis and therapy.
METHODS
The China Paroxysmal Dyskinesia Collaborative Group was composed of departments of neurology from 22 hospitals. Clinical manifestations and proline-rich transmembrane protein 2 screening results were recorded using unified paroxysmal kinesigenic dyskinesia registration forms. Genotype-phenotype correlation analyses were conducted in patients with and without proline-rich transmembrane protein 2 mutations. High-knee exercises were applied in partial patients as a new diagnostic test to induce attacks.
RESULTS
Kinesigenic triggers, male predilection, dystonic attacks, aura, complicated forms of paroxysmal kinesigenic dyskinesia, clustering in patients with family history, and dramatic responses to antiepileptic treatment were the prominent features in this multicenter study. Clinical analysis showed that proline-rich transmembrane protein 2 mutation carriers were prone to present at a younger age and have longer attack duration, bilateral limb involvement, choreic attacks, a complicated form of paroxysmal kinesigenic dyskinesia, family history, and more forms of dyskinesia. The new high-knee-exercise test efficiently induced attacks and could assist in diagnosis.
CONCLUSIONS
We propose recommendations regarding diagnostic criteria for paroxysmal kinesigenic dyskinesia based on this large clinical study of paroxysmal kinesigenic dyskinesia. The findings offered some new insights into the diagnosis and treatment of paroxysmal kinesigenic dyskinesia and might help in building standardized paroxysmal kinesigenic dyskinesia clinical evaluations and therapies. © 2020 International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 32392383
doi: 10.1002/mds.28061
doi:

Substances chimiques

Nerve Tissue Proteins 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1428-1437

Informations de copyright

© 2020 International Parkinson and Movement Disorder Society.

Références

Kertesz A. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. Neurology 1967;17:680-690.
Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 2004;63:2280-2287.
Bhatia KP, Schneider SA. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesia. Mov Disord 2012;27:707.
Wang JL, Cao L, Li XH, et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain 2011;134(Pt. 12):3493-3501.
Chen WJ, Lin Y, Xiong ZQ, et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet 2011;43:1252-1255.
Zhang XJ, Xu ZY, Wu YC, Tan EK. Paroxysmal movement disorders: recent advances and proposal of a classification system. Parkinsonism Relat Disord 2019;59:131-139.
Meneret A, Gaudebout C, Riant F, Vidailhet M, Depienne C, Roze E. PRRT2 mutations and paroxysmal disorders. Eur J Neurol 2013;20:872-878.
Heron SE, Dibbens LM. Role of PRRT2 in common paroxysmal neurological disorders: a gene with remarkable pleiotropy. J Med Genet 2013;50:133-139.
Schubert J, Paravidino R, Becker F, et al. PRRT2 mutations are the major cause of benign familial infantile seizures. Hum Mutat 2012;33:1439-1443.
Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain 2015;138(Pt. 12):3476-3495.
Gardella E, Becker F, Moller RS, et al. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol 2016;79:428-436.
Tian WT, Huang XJ, Mao X, et al. Proline-rich transmembrane protein 2-negative paroxysmal kinesigenic dyskinesia: clinical and genetic analyses of 163 patients. Mov Disord 2018;33:459-467.
Wang HX, Li HF, Liu GL, Wen XD, Wu ZY. Mutation analysis of MR-1, SLC2A1, and CLCN1 in 28 PRRT2-negative paroxysmal kinesigenic dyskinesia patients. Chin Med J (Engl) 2016;129:1017-1021.
Huang XJ, Wang T, Wang JL, et al. Paroxysmal kinesigenic dyskinesia: clinical and genetic analyses of 110 patients. Neurology 2015;85:1546-1553.
Tan LC, Methawasin K, Teng EW, et al. Clinico-genetic comparisons of paroxysmal kinesigenic dyskinesia patients with and without PRRT2 mutations. Eur J Neurol 2014;21:674-678.
Mao CY, Shi CH, Song B, et al. Genotype-phenotype correlation in a cohort of paroxysmal kinesigenic dyskinesia cases. J Neurol Sci 2014;340:91-93.
Ostrowsky K, Isnard J, Ryvlin P, Guenot M, Fischer C, Mauguiere F. Functional mapping of the insular cortex: clinical implication in temporal lobe epilepsy. Epilepsia 2000;41:681-686.
Kim DW, Lee SK, Yun CH, et al. Parietal lobe epilepsy: the semiology, yield of diagnostic workup, and surgical outcome. Epilepsia 2004;45:641-649.
Afif A, Minotti L, Kahane P, Hoffmann D. Anatomofunctional organization of the insular cortex: a study using intracerebral electrical stimulation in epileptic patients. Epilepsia 2010;51:2305-2315.
Zhou B, Chen Q, Zhang Q, et al. Hyperactive putamen in patients with paroxysmal kinesigenic choreoathetosis: a resting-state functional magnetic resonance imaging study. Mov Disord 2010;25:1226-1231.
Luo C, Chen Y, Song W, Chen Q, Gong Q, Shang HF. Altered intrinsic brain activity in patients with paroxysmal kinesigenic dyskinesia by PRRT2 mutation: altered brain activity by PRRT2 mutation. Neurol Sci 2013;34:1925-1931.
Ren J, Lei D, Yang T, et al. Increased interhemispheric resting-state functional connectivity in paroxysmal kinesigenic dyskinesia: a resting-state fMRI study. J Neurol Sci 2015;351:93-98.
Hsiao FJ, Hsu WY, Chen WT, Chen RS, Lin YY. Abnormal somatosensory synchronization in patients with paroxysmal kinesigenic dyskinesia: a magnetoencephalographic study. Clin EEG Neurosci 2017;48:288-294.
Valente P, Castroflorio E, Rossi P, et al. PRRT2 is a key component of the Ca(2+)-dependent neurotransmitter release machinery. Cell Rep 2016;15:117-131.
Michetti C, Castroflorio E, Marchionni I, et al. The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations. Neurobiol Dis 2017;99:66-83.
Liu YT, Nian FS, Chou WJ, et al. PRRT2 mutations lead to neuronal dysfunction and neurodevelopmental defects. Oncotarget 2016;7:39184-39196.
Fruscione F, Valente P, Sterlini B, et al. PRRT2 controls neuronal excitability by negatively modulating Na+ channel 1.2/1.6 activity. Brain 2018;141:1000-1016.
Maini I, Iodice A, Spagnoli C, et al. Expanding phenotype of PRRT2 gene mutations: a new case with epilepsy and benign myoclonus of early infancy. Eur J Paediatr Neurol 2016;20:454-456.
Frohlich K, Winder K, Linker RA, et al. Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis. J Neurol 2018;265:2277-2283.
Hur YJ, Hwang T. Secondary paroxysmal dyskinesia associated with 2009 H1N1 infection. Korean J Pediatr 2013;56:42-44.
Jin D, Yoon WT, Suh BC, Moon HS, Chung PW, Kim YB. Exacerbation of idiopathic paroxysmal kinesigenic dyskinesia in remission state caused by secondary hypoparathyroidism with hypocalcemia after thyroidectomy: evidence for ion channelopathy. Brain Dev 2012;34:840-843.
Saiki M, Saiki S, Gondo Y, Murata KY, Sakai K, Hirose G. [Ictal alteration of 99mTc ECD SPECT imaging in a patient with secondary paroxysmal kinesigenic dyskinesia caused by hyperglycemia]. [Article in Japanese]. Rinsho Shinkeigaku 2005;45:312-316.
Blakeley J, Jankovic J. Secondary causes of paroxysmal dyskinesia. Adv Neurol 2002;89:401-420.
Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord 2002;17:726-734.

Auteurs

Xiao-Jun Huang (XJ)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Shi-Ge Wang (SG)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Xia-Nan Guo (XN)

Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China.
McKusick-Zhang Center for Genetic Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, China.
Department of Nephrology, the First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Wo-Tu Tian (WT)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Fei-Xia Zhan (FX)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Ze-Yu Zhu (ZY)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Xiao-Meng Yin (XM)

Department of Neurology, Xiangya Hospital, Central South University, State Key Laboratory of Medical Genetics, Changsha, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Qing Liu (Q)

Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Kai-Li Yin (KL)

Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China.
McKusick-Zhang Center for Genetic Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Xiao-Rong Liu (XR)

Institute of Neuroscience and The Second Affiliated Hospital of Guangzhou Medical University, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Yu Zhang (Y)

Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Zhen-Guo Liu (ZG)

Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Xiao-Li Liu (XL)

Department of Neurology, Fengxian District Central Hospital, Shanghai Jiao Tong University Affiliated to Sixth People's Hospital South Campus, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Lan Zheng (L)

Department of Neurology, Minhang Hospital, Fudan University, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Tian Wang (T)

Department of Neurology, The Central Hospital of Wuhan, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Li Wu (L)

Department of Neurology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Tian-Yi Rong (TY)

Department of Neurology, Shidong Hospital of Yangpu District, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Yan Wang (Y)

Department of Neurology, The First Hospital Affiliated to Anhui University of Science and Technology, Huainan, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Mei Zhang (M)

Department of Neurology, The First Hospital Affiliated to Anhui University of Science and Technology, Huainan, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Guang-Hui Bi (GH)

Department of Neurology, Dongying People's Hospital, Dongying, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Wei-Guo Tang (WG)

Department of Neurology, Zhoushan Hospital, Zhoushan, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Chao Zhang (C)

Department of Neurology, Suzhou Municipal Hospital, Suzhou, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Ping Zhong (P)

Department of Neurology, Suzhou Municipal Hospital, Suzhou, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Chun-Yu Wang (CY)

Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Jian-Guang Tang (JG)

Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Wei Lu (W)

Department of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Ru-Xu Zhang (RX)

Department of Neurology, The Third Xiangya Hospital, Central South University, Changsha, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Guo-Hua Zhao (GH)

Department of Neurology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Xun-Hua Li (XH)

Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Hua Li (H)

Department of Neurology, Guangdong 999 Brain Hospital, Guangzhou, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Tao Chen (T)

Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Hai-Yan Li (HY)

Department of Neurology, Anyang People's Hospital, Anyang, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Xiao-Guang Luo (XG)

Department of Neurology, Shenzhen People's Hospital, Shenzhen, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Yan-Yan Song (YY)

Department of Biostatistics, Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Hui-Dong Tang (HD)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Xing-Hua Luan (XH)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Hai-Yan Zhou (HY)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Bei-Sha Tang (BS)

Department of Neurology, Xiangya Hospital, Central South University, State Key Laboratory of Medical Genetics, Changsha, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Sheng-Di Chen (SD)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Li Cao (L)

Department of Neurology, Rui Jin Hospital and Rui Jin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
China Paroxysmal Dyskinesia Collaborative Group (CPDCG), Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH